PureTech Health plc (PRTC)
| Market Cap | 379.12M -3.1% |
| Revenue (ttm) | 6.39M +1,265.6% |
| Net Income | 50.68M |
| EPS | 0.20 |
| Shares Out | 24.03M |
| PE Ratio | 7.48 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 970 |
| Open | 15.78 |
| Previous Close | 15.86 |
| Day's Range | 15.78 - 15.96 |
| 52-Week Range | 13.30 - 20.00 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About PRTC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]
Financial Performance
Financial StatementsNews
PureTech to Present at the Leerink Partners Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Leerink Partners Global Healthcare Conference.
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone in IPF.
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference.
PureTech Appoints Robert Lyne as Chief Executive Officer
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innov...
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis.
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia.
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.
PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.
PureTech Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference.
PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive O...
PureTech Announces Annual Results for Year Ended December 31, 2024
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints Peel Hunt as Joint UK Corporate Broker.